279 related articles for article (PubMed ID: 16182177)
41. Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia.
Schetelig J; Thiede C; Bornhäuser M; Schwerdtfeger R; Kiehl M; Beyer J; Kröger N; Hensel M; Scheffold C; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W
Ann Hematol; 2002; 81 Suppl 2():S47-8. PubMed ID: 12611075
[TBL] [Abstract][Full Text] [Related]
42. Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies.
Alessandrino EP; Bernasconi P; Colombo AA; Caldera D; Malcovati L; Troletti D; Vanelli L; Varettoni M; Montanari F; Lazzarino M
Bone Marrow Transplant; 2004 Dec; 34(12):1039-45. PubMed ID: 15516936
[TBL] [Abstract][Full Text] [Related]
43. Impact of transplanted CD34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation.
Sohn SK; Kim JG; Kim DH; Lee NY; Suh JS; Lee KB
Bone Marrow Transplant; 2003 Jun; 31(11):967-72. PubMed ID: 12774046
[TBL] [Abstract][Full Text] [Related]
44. [Outcome of allogeneic stem cell transplantation in patients older than 50 years of age].
Takada S; Okamoto S; Sakamaki H; Maruta A; Kanamori H; Nishimura M; Aotsuka N; Kishi K; Miyawaki S;
Rinsho Ketsueki; 2002 Oct; 43(10):904-10. PubMed ID: 12462025
[TBL] [Abstract][Full Text] [Related]
45. Reduced-intensity non-T-cell depleted HLA-haploidentical stem cell transplantation for older patients based on the concept of feto-maternal tolerance.
Obama K; Utsunomiya A; Takatsuka Y; Takemoto Y
Bone Marrow Transplant; 2004 Nov; 34(10):897-9. PubMed ID: 15361902
[TBL] [Abstract][Full Text] [Related]
46. Haematopoietic stem cell transplantation with non-myeloablative conditioning in the outpatient setting: results, complications and admission requirements in a single institution.
Petersen SL; Madsen HO; Ryder LP; Svejgaard A; Jakobsen BK; Sengeløv H; Heilmann C; Dickmeiss E; Vindeløv LL
Br J Haematol; 2004 Apr; 125(2):225-31. PubMed ID: 15059146
[TBL] [Abstract][Full Text] [Related]
47. Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): successful management by allogeneic hematopoietic stem cell transplant (HSCT).
Trobaugh-Lotrario AD; Kletzel M; Quinones RR; McGavran L; Proytcheva MA; Hunger SP; Malcolm J; Schissel D; Hild E; Giller RH
Bone Marrow Transplant; 2005 Jan; 35(2):143-9. PubMed ID: 15558042
[TBL] [Abstract][Full Text] [Related]
48. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.
Neumann F; Graef T; Tapprich C; Vaupel M; Steidl U; Germing U; Fenk R; Hinke A; Haas R; Kobbe G
Bone Marrow Transplant; 2005 Jun; 35(11):1089-93. PubMed ID: 15821769
[TBL] [Abstract][Full Text] [Related]
49. Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia.
Park J; Lee MH; Lee HR; Park SH; Lee SH; Lee KE; Lee H; Park JO; Kim K; Jung CW; Im YH; Kang WK; Ko YH; Park K
Bone Marrow Transplant; 2003 Nov; 32(9):889-95. PubMed ID: 14561989
[TBL] [Abstract][Full Text] [Related]
50. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.
Wong R; Shahjahan M; Wang X; Thall PF; De Lima M; Khouri I; Gajewski J; Alamo J; Couriel D; Andersson BS; Donato M; Hosing C; Komanduri K; Anderlini P; Molldrem J; Ueno NT; Estey E; Ippoliti C; Champlin R; Giralt S
Biol Blood Marrow Transplant; 2005 Feb; 11(2):108-14. PubMed ID: 15682071
[TBL] [Abstract][Full Text] [Related]
51. CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors.
Popat U; Carrum G; May R; Lamba R; Krance RA; Heslop HE; Brenner MK
Bone Marrow Transplant; 2005 Jun; 35(12):1127-32. PubMed ID: 15834432
[TBL] [Abstract][Full Text] [Related]
52. Haplotype mismatched transplantation using high doses of peripheral blood CD34+ cells together with stratified conditioning regimens for high-risk adult acute myeloid leukemia patients: a pilot study in a single Korean institution.
Kim HJ; Min WS; Kim YJ; Kim DW; Lee JW; Kim CC
Bone Marrow Transplant; 2005 May; 35(10):959-64. PubMed ID: 15778730
[TBL] [Abstract][Full Text] [Related]
53. Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation.
Kim JG; Sohn SK; Kim DH; Baek JH; Lee KB; Min WS; Kim CC; Lee MH; Lee JJ; Chung IJ; Kim HJ; Lee JW
Bone Marrow Transplant; 2005 Mar; 35(5):489-95. PubMed ID: 15654350
[TBL] [Abstract][Full Text] [Related]
54. Hemopoietic cell transplantation for the myelodysplastic syndromes.
Scott BL; Deeg HJ
Arch Immunol Ther Exp (Warsz); 2005; 53(4):297-307. PubMed ID: 16088314
[TBL] [Abstract][Full Text] [Related]
55. Superior survival of blood and marrow stem cell recipients given maternal grafts over recipients given paternal grafts.
Tamaki S; Ichinohe T; Matsuo K; Hamajima N; Hirabayashi N; Dohy H;
Bone Marrow Transplant; 2001 Aug; 28(4):375-80. PubMed ID: 11571510
[TBL] [Abstract][Full Text] [Related]
56. Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphoma.
Yuji K; Miyakoshi S; Kato D; Miura Y; Myojo T; Murashige N; Kishi Y; Kobayashi K; Kusumi E; Narimatsu H; Hamaki T; Matsumura T; Kami M; Fukuda T; Masuo S; Masuoka K; Wake A; Ueyama J; Yoneyama A; Miyamoto K; Nagoshi H; Matsuzaki M; Morinaga S; Muto Y; Takeue Y; Taniguchi S;
Biol Blood Marrow Transplant; 2005 Apr; 11(4):314-8. PubMed ID: 15812397
[TBL] [Abstract][Full Text] [Related]
57. [The clinical research of nonmyeloablative allogeneic peripheral blood hematopoietic stem cells transplantation for hematological diseases].
Ai HS; Yu CL; Wang DH; Guo M; Qiao JH; Shi BF; Sun WJ; Zhang S; Sun QY; Yao B
Zhonghua Xue Ye Xue Za Zhi; 2003 Feb; 24(2):86-9. PubMed ID: 12697103
[TBL] [Abstract][Full Text] [Related]
58. Transplant strategies for myelodysplastic syndrome.
McCarty J
Best Pract Res Clin Haematol; 2004 Dec; 17(4):559-72. PubMed ID: 15494294
[TBL] [Abstract][Full Text] [Related]
59. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia.
Medeiros BC; Kolhouse JF; Cagnoni PJ; Ryder J; Nieto Y; Rabinovitch R; Shpall EJ; Bearman SI; Jones RB; McSweeney PA
Bone Marrow Transplant; 2003 Jun; 31(11):1053-5. PubMed ID: 12774059
[TBL] [Abstract][Full Text] [Related]
60. [Treatment outcome of myelodysplastic syndrome patients younger than 60 years old].
Matsushima T; Handa H; Yokohama A; Sakura T; Okamoto K; Kawamura T; Tsumita Y; Murayama K; Isoda A; Jinbo T; Hirabyashi H; Sawamura M; Karasawa M; Shimano S; Tsukamoto N; Miyawaki S; Nojima Y; Murakami H
Rinsho Ketsueki; 2003 Oct; 44(10):1004-9. PubMed ID: 14639946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
